Corline Biomedical AB
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CLBIO.ST research report →
Companywww.corline.se
Corline Biomedical AB develops, manufactures, and markets heparin based solutions to enhance kidney transplantation, cell therapies, and regenerative medicine applications. Its products are based on Corline Heparin Conjugate (CHC) technology, a heparin conjugate that is used as stand-alone pharmaceutical compound. The company's products include Renaparin for use in the treatment of end stage renal failure; Cytoparin, a cell therapy that is used for the treatment of patients with type 1 diabetes; CHC, which is used for the treatment of soft tissue injuries; medical devices; and CHS, a coronary stent.
- CEO
- Henrik Nittmar
- IPO
- 2015
- Employees
- 13
- HQ
- Uppsala, SE
Price Chart
Valuation
- Market Cap
- $478.24M
- P/E
- -33.15
- P/S
- 48.37
- P/B
- 4.67
- EV/EBITDA
- -31.76
- Div Yield
- 0.00%
Profitability
- Gross Margin
- -45.18%
- Op Margin
- -140.13%
- Net Margin
- -143.06%
- ROE
- -16.07%
- ROIC
- -12.64%
Growth & Income
- Revenue
- $7.65M · -21.73%
- Net Income
- $-14,714,000 · 36.56%
- EPS
- $-0.59 · 44.34%
- Op Income
- $-14,208,000
- FCF YoY
- -9.92%
Performance & Tape
- 52W High
- $27.20
- 52W Low
- $9.48
- 50D MA
- $16.31
- 200D MA
- $16.70
- Beta
- 0.30
- Avg Volume
- 13.51K
Get TickerSpark's AI analysis on CLBIO.ST
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our CLBIO.ST Coverage
We haven't published any research on CLBIO.ST yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate CLBIO.ST Report →